Obstructive sleep apnea (OSA) is wreaking havoc on individuals and healthcare systems alike, contributing to hypertension, diabetes, depression, and even stroke, while costing the U.S. economy a staggering $150 billion annually. (1-2) Despite its devastating impact, OSA remains underdiagnosed and undertreated. A recent study found untreated OSA patients incur healthcare costs averaging $19,566 per year, primarily due to inpatient care. (3)

Vivos Therapeutics, a leader in innovative airway health solutions, is taking bold steps to combat this growing epidemic. By providing integrated, non-invasive solutions tailored for early intervention and prevention, Vivos is redefining how OSA is treated, with the aim of improving patient outcomes and decreasing the financial burden on healthcare systems.

"Sleep apnea doesn't just disrupt sleep; it destroys lives and drains resources. And the traditional CPAP-centered models of treatment have fallen short," said Kirk Huntsman, Chairman and CEO of Vivos Therapeutics. "We need to move beyond outdated paradigms like CPAP therapy, which merely manages symptoms over a lifetime. At Vivos, we're focused on rehabilitating and restoring patient airways such that within about 9-12 months, no further intervention is necessary. That's our goal, and it's very different from what sleep medicine has been offering patients up until now."

 

Source: prnewswire.com

Report Abuse